What compounding describes
FDA describes compounding as preparing a medication by combining, mixing or altering ingredients for a patient’s needs. Compounded drugs are not FDA-approved and do not undergo the agency’s premarket review for safety, effectiveness and quality.[source]
That statement concerns the finished preparation. It should remain visible even when one of its ingredients is widely used.
Ask why a custom blend is proposed
The clinician should be able to explain the intended benefit of the specific combination or vehicle. A personalized label alone is not the explanation. Ask about reasonable alternatives and how the proposed formula fits the concern.
A standard product and a compounded blend may differ in more than branding. Compare their actual ingredients and instructions rather than assuming interchangeability.
Separate the active from the formulation
Professional retinoid guidance can inform treatment selection without validating every custom blend. AAD’s overview provides ingredient-family context; it does not certify an online provider’s named cream.[source]
Ask whether any cited study examined the finished product, a similar ingredient or a different preparation. Preserve that difference when reading outcome claims.
The pharmacy is part of the practical comparison
Confirm who dispenses the medicine and how to ask about the label, storage and beyond-use information. The provider, prescriber and pharmacy can have separate responsibilities. Knowing whom to contact makes the arrangement clearer.
If directions or ingredients appear inconsistent, ask for clarification rather than reconstructing them from another website.
Choose with the full care arrangement in view
Compare the actual preparation, rationale, total cost and medical follow-up. This publication does not declare every custom cream superior or inferior as a class. The relevant question is whether the specific prescription and its evidence fit the clinical situation.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Accessed October 8, 2026.
- FDA — Compounding and the FDA: Questions and AnswersCompounded drugs are not FDA-approved; oversight and evidence limitations
- American Academy of Dermatology — Retinoid or retinol?Dermatology guidance on retinoids, irritation and pregnancy